Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Oncopeptides Innovation 1 AB
AB
Active
Org 5593798803
Luntmakargatan 46, 111 37
Stockholm
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2022 · 4 years old
0 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Oncopeptides Innovation 1 AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
0M
-1M
-1M
2022: 0M
0M
2022
2022: 0M
0M
2022
2023: 0M
0M
2023
2024: 0M
0M
2024
2025: 0M
0M
2025
EBITDA
SEK millions
0M
-5M
-9M
-14M
-19M
2022: -1M
-1M
2022
2022: -1M (0% vs 2022)
-1M
0%
2022
2023: -7M (-600% vs 2022)
-7M
-600%
2023
2024: -15M (-114% vs 2023)
-15M
-114%
2024
2025: -7M (+53% vs 2024)
-7M
+53%
2025
Income statement
SEK thousands
Item
2025
2024
2023
2022
2022
Revenue
0
−0
0
0
0
Staff expenses
—
—
—
−0
—
EBITDA
−7 024
−14 541
−7 016
−693
−693
Depreciation & amort.
—
—
—
−0
−0
EBIT
−7 024
−14 541
−7 016
−693
−693
Net financials
56
119
41
0
—
Profit before tax
0
0
1
7
7
Tax
—
—
—
1
−1
Net profit
—
0
1
6
6
Balance sheet
SEK thousands
Item
2025
2024
2023
2022
2022
Total assets
36 313
27 535
9 363
593
593
Equity
31
31
31
31
31
Long-term debt
—
—
—
0
0
Short-term debt
36 281
27 504
9 331
563
563
Total debt
36 281
27 504
9 331
563
563
Financial ratios
5-year trend
EBITDA margin
<−999 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2022
2025
Equity ratio
0,1 %
This company
38,2 %
Market median
This company
Market median
100% below market
2022
2025
Return on equity
0,0 %
This company
18,4 %
Market median
This company
Market median
100% below market
2022
2025
Net profit margin
0,0 %
This company
8,1 %
Market median
This company
Market median
100% below market
2022
2025
Asset turnover
0,00×
This company
1,12×
Market median
This company
Market median
100% below market
2022
2025
Debt / equity
>999×
This company
0,62×
Market median
This company
Market median
>999% above market
2022
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-05-10 – 2022-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-05-01 – 2022-12-31
View
PDF
More on Oncopeptides Innovation 1 AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
